---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-080571"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:14:48.376571+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# BioXcel Therapeutics amends ARx supply agreement to reduce minimum annual payments over next three years

## Summary
- Amendment reduces specified minimum annual payment due to ARx for next three years starting 2024.
- Thereafter, minimum annual payments only required if FDA approves sNDA or NDA for listed indications.
- No specific financial terms or amounts disclosed in the filing.

## SEC filing metadata
- accession: 0001104659-24-080571
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/0001104659-24-080571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924080571/tm2419377d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-080571
- JSON: https://secwatch.observer/filing/0001104659-24-080571.json
- Plain text: https://secwatch.observer/filing/0001104659-24-080571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.